{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:23:44Z","timestamp":1793607824196,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["ARUK-PPG2014B-7"],"award-info":[{"award-number":["ARUK-PPG2014B-7"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lee Trust, NZ"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is one of the most common neurodegenerative diseases, most commonly characterised by motor dysfunction, but also with a high prevalence of cognitive decline in the decades following diagnosis\u2014a condition known as Parkinson\u2019s disease dementia (PDD). Although several metabolic disruptions have been identified in PD, there has yet to be a multi-regional analysis of multiple metabolites conducted in PDD brains. This discovery study attempts to address this gap in knowledge. A semi-targeted liquid chromatography\u2013mass spectrometry analysis of nine neuropathologically-confirmed PDD cases vs nine controls was performed, looking at nine different brain regions, including the cingulate gyrus, cerebellum, hippocampus, motor cortex, medulla, middle temporal gyrus, pons, substantia nigra and primary visual cortex. Case\u2013control differences were determined by multiple t-tests followed by 10% FDR correction. Of 64 identified analytes, 49 were found to be altered in at least one region of the PDD brain. These included metabolites from several pathways, including glucose and purine metabolism and the TCA cycle, with widespread increases in fructose, inosine and ribose-5-phosphate, as well as decreases in proline, serine and deoxyguanosine. Higher numbers of alterations were observed in PDD brain regions that are affected during earlier \u03b1-synuclein Braak stages\u2014with the exception of the cerebellum, which showed an unexpectedly high number of metabolic changes. PDD brains show multi-regional alterations in glucose and purine metabolic pathways that reflect the progression of \u03b1-synuclein Braak staging. Unexpectedly, the cerebellum also shows a high number of metabolic changes.<\/jats:p>","DOI":"10.1038\/s41531-023-00488-y","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T04:03:47Z","timestamp":1681963427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Multi-regional alterations in glucose and purine metabolic pathways in the Parkinson\u2019s disease dementia brain"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-0986","authenticated-orcid":false,"given":"Melissa","family":"Scholefield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Unwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth J. S.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes, O. B. & Storstein, A. Epidemiology of Parkinson\u2019s disease. J. Neural. Transm. 124, 901\u2013905 (2017).","journal-title":"J. Neural. Transm."},{"key":"488_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8, S3\u2013S8 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"488_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jns.2017.01.012","volume":"374","author":"HA Hanagasi","year":"2017","unstructured":"Hanagasi, H. A., Tufekcioglu, Z. & Emre, M. Dementia in Parkinson\u2019s disease. J. Neurol. Sci. 374, 26\u201331 (2017).","journal-title":"J. Neurol. Sci."},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2967\/jnumed.111.089946","volume":"52","author":"NI Bohnen","year":"2011","unstructured":"Bohnen, N. I. et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J. Nucl. Med. 52, 848\u2013855 (2011).","journal-title":"J. Nucl. Med."},{"key":"488_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","volume":"35","author":"L Dunn","year":"2014","unstructured":"Dunn, L. et al. Dysregulation of glucose metabolism is an early event in sporadic Parkinson\u2019s disease. Neurobiol. Aging 35, 1111\u20131115 (2014).","journal-title":"Neurobiol. Aging"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian, J. et al. Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348\u2013355 (1994).","journal-title":"Ann. Neurol."},{"key":"488_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000346370","volume":"12","author":"NR McFarland","year":"2013","unstructured":"McFarland, N. R., Burdett, T., Desjardins, C. A., Frosch, M. P. & Schwarzschild, M. A. Postmortem brain levels of urate and precursors in Parkinson\u2019s disease and related disorders. Neurodegener. Dis. 12, 189\u2013198 (2013).","journal-title":"Neurodegener. Dis."},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0197-0186(02)00225-5","volume":"43","author":"GE Gibson","year":"2003","unstructured":"Gibson, G. E. et al. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson\u2019s disease. Neurochem. Int. 43, 129\u2013135 (2003).","journal-title":"Neurochem. Int."},{"key":"488_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0829-3","volume":"18","author":"JS Park","year":"2018","unstructured":"Park, J. S., Davis, R. L. & Sue, C. M. Mitochondrial dysfunction in Parkinson\u2019s disease: new mechanistic insights and therapeutic perspectives. Curr. Neurol. Neurosci. Rep. 18, 21 (2018).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"488_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JPD-201981","volume":"11","author":"M Borsche","year":"2021","unstructured":"Borsche, M., Pereira, S. L., Klein, C. & Grunewald, A. Mitochondria and Parkinson\u2019s disease: clinical, molecular, and translational aspects. J. Parkinsons Dis. 11, 45\u201360 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"488_CR11","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.arr.2021.101263","volume":"67","author":"PA Dionisio","year":"2021","unstructured":"Dionisio, P. A., Amaral, J. D. & Rodrigues, C. M. P. Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res. Rev. 67, 101263 (2021).","journal-title":"Ageing Res. Rev."},{"key":"488_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-017-0340-9","volume":"10","author":"L Puspita","year":"2017","unstructured":"Puspita, L., Chung, S. Y. & Shim, J. W. Oxidative stress and cellular pathologies in Parkinson\u2019s disease. Mol. Brain 10, 53 (2017).","journal-title":"Mol. Brain"},{"key":"488_CR13","doi-asserted-by":"publisher","first-page":"147118","DOI":"10.1016\/j.brainres.2020.147118","volume":"1748","author":"B Toczylowska","year":"2020","unstructured":"Toczylowska, B., Zieminska, E., Michalowska, M., Chalimoniuk, M. & Fiszer, U. Changes in the metabolic profiles of the serum and putamen in Parkinson\u2019s disease patients - In vitro and in vivo NMR spectroscopy studies. Brain Res. 1748, 147118 (2020).","journal-title":"Brain Res."},{"key":"488_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/cells8020096","volume":"8","author":"B Pesch","year":"2019","unstructured":"Pesch, B. et al. Impairment of motor function correlates with neurometabolite and brain iron alterations in Parkinson\u2019s disease. Cells 8, 96 (2019).","journal-title":"Cells"},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1046\/j.1471-4159.2002.00871.x","volume":"81","author":"JO Rinne","year":"2002","unstructured":"Rinne, J. O. et al. Increased brain histamine levels in Parkinson\u2019s disease but not in multiple system atrophy. J. Neurochem. 81, 954\u2013960 (2002).","journal-title":"J. Neurochem."},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"488_CR17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ana.24937","volume":"81","author":"K Seidel","year":"2017","unstructured":"Seidel, K. et al. Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Ann. Neurol. 81, 898\u2013903 (2017).","journal-title":"Ann. Neurol."},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F","volume":"47","author":"SM Solano","year":"2000","unstructured":"Solano, S. M., Miller, D. W., Augood, S. J., Young, A. B. & Penney, J. B. Jr Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson\u2019s disease. Ann. Neurol. 47, 201\u2013210 (2000).","journal-title":"Ann. Neurol."},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00401-002-0655-0","volume":"105","author":"YS Piao","year":"2003","unstructured":"Piao, Y. S. et al. Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. Acta Neuropathol. 105, 403\u2013409 (2003).","journal-title":"Acta Neuropathol."},{"key":"488_CR20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/brain\/aws360","volume":"136","author":"T Wu","year":"2013","unstructured":"Wu, T. & Hallett, M. The cerebellum in Parkinson\u2019s disease. Brain 136, 696\u2013709 (2013).","journal-title":"Brain"},{"key":"488_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/archneur.1992.00530360060019","volume":"49","author":"RF Peppard","year":"1992","unstructured":"Peppard, R. F. et al. Cerebral glucose metabolism in Parkinson\u2019s disease with and without dementia. Arch. Neurol. 49, 1262\u20131268 (1992).","journal-title":"Arch. Neurol."},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1002\/ana.410150723","volume":"15","author":"DE Kuhl","year":"1984","unstructured":"Kuhl, D. E., Metter, E. J., Riege, W. H. & Markham, C. H. Patterns of cerebral glucose utilization in Parkinson\u2019s disease and Huntington\u2019s disease. Ann. Neurol. 15, S119\u2013S125 (1984).","journal-title":"Ann. Neurol."},{"key":"488_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00429-010-0246-0","volume":"214","author":"P Borghammer","year":"2010","unstructured":"Borghammer, P. et al. Cortical hypometabolism and hypoperfusion in Parkinson\u2019s disease is extensive: probably even at early disease stages. Brain Struct. Funct. 214, 303\u2013317 (2010).","journal-title":"Brain Struct. Funct."},{"key":"488_CR24","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/JCI129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai, R. et al. Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases. J. Clin. Invest. 129, 4539\u20134549 (2019).","journal-title":"J. Clin. Invest."},{"key":"488_CR25","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ene.14470","volume":"27","author":"FJ Jimenez-Jimenez","year":"2020","unstructured":"Jimenez-Jimenez, F. J., Alonso-Navarro, H., Garcia-Martin, E. & Agundez, J. A. G. Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson\u2019s disease: review and meta-analysis. Eur. J. Neurol. 27, 2336\u20132347 (2020).","journal-title":"Eur. J. Neurol."},{"key":"488_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000288676","volume":"60","author":"H Lehnert","year":"1993","unstructured":"Lehnert, H. & Wurtman, R. J. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. Psychother. Psychosom. 60, 18\u201332 (1993).","journal-title":"Psychother. Psychosom."},{"key":"488_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fneur.2018.00806","volume":"9","author":"RL O\u2019Gorman Tuura","year":"2018","unstructured":"O\u2019Gorman Tuura, R. L., Baumann, C. R. & Baumann-Vogel, H. Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease. Front. Neurol. 9, 806 (2018).","journal-title":"Front. Neurol."},{"key":"488_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ana.410200106","volume":"20","author":"SJ Kish","year":"1986","unstructured":"Kish, S. J. et al. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson\u2019s disease: correlation with striatal dopamine loss. Ann. Neurol. 20, 26\u201331 (1986).","journal-title":"Ann. Neurol."},{"key":"488_CR29","doi-asserted-by":"publisher","first-page":"e30918","DOI":"10.1371\/journal.pone.0030918","volume":"7","author":"UE Emir","year":"2012","unstructured":"Emir, U. E., Tuite, P. J. & Oz, G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS ONE 7, e30918 (2012).","journal-title":"PLoS ONE"},{"key":"488_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11604-017-0714-z","volume":"36","author":"EEA Elmaki","year":"2018","unstructured":"Elmaki, E. E. A., Gong, T., Nkonika, D. M. & Wang, G. Examining alterations in GABA concentrations in the basal ganglia of patients with Parkinson\u2019s disease using MEGA-PRESS MRS. Jpn. J. Radiol. 36, 194\u2013199 (2018).","journal-title":"Jpn. J. Radiol."},{"key":"488_CR31","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1212\/WNL.0000000000006007","volume":"91","author":"MJ Firbank","year":"2018","unstructured":"Firbank, M. J. et al. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology 91, e675\u2013e685 (2018).","journal-title":"Neurology"},{"key":"488_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/metabo11090569","volume":"11","author":"M Scholefield","year":"2021","unstructured":"Scholefield, M. et al. Substantively lowered levels of pantothenic acid (Vitamin B5) in several regions of the human brain in Parkinson\u2019s disease dementia. Metabolites 11, 569 (2021).","journal-title":"Metabolites"},{"key":"488_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.bbadis.2016.06.002","volume":"1862","author":"S Patassini","year":"2016","unstructured":"Patassini, S. et al. Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington\u2019s disease human brain. Biochim. Biophys. Acta 1862, 1650\u20131662 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"488_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep27524","volume":"6","author":"J Xu","year":"2016","unstructured":"Xu, J. et al. Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer\u2019s disease: metabolic basis for dementia. Sci. Rep. 6, 27524 (2016).","journal-title":"Sci. Rep."},{"key":"488_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbrc.2015.10.140","volume":"468","author":"S Patassini","year":"2015","unstructured":"Patassini, S. et al. Identification of elevated urea as a severe, ubiquitous metabolic defect in the brain of patients with Huntington\u2019s disease. Biochem. Biophys. Res. Commun. 468, 161\u2013166 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"488_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/metabo9060113","volume":"9","author":"S Patassini","year":"2019","unstructured":"Patassini, S. et al. Cerebral vitamin B5 (d-pantothenic acid) deficiency as a potential cause of metabolic perturbation and neurodegeneration in Huntington\u2019s disease. Metabolites 9, 113 (2019).","journal-title":"Metabolites"},{"key":"488_CR37","doi-asserted-by":"publisher","first-page":"E11293","DOI":"10.1073\/pnas.1711243115","volume":"114","author":"RR Handley","year":"2017","unstructured":"Handley, R. R. et al. Brain urea increase is an early Huntington\u2019s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases. Proc. Natl Acad. Sci. USA 114, E11293\u2013E11302 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"488_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bbrc.2020.05.015","volume":"527","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer\u2019s disease. Biochem. Biophys. Res. Commun. 527, 676\u2013681 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"488_CR39","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1039\/C7MT00074J","volume":"9","author":"J Xu","year":"2017","unstructured":"Xu, J. et al. Evidence for widespread, severe brain copper deficiency in Alzheimer\u2019s dementia. Metallomics 9, 1106\u20131119 (2017).","journal-title":"Metallomics"},{"key":"488_CR40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/metabo10110438","volume":"10","author":"M Scholefield","year":"2020","unstructured":"Scholefield, M. et al. Effects of alterations of post-mortem delay and other tissue-collection variables on metabolite levels in human and rat brain. Metabolites 10, 438 (2020).","journal-title":"Metabolites"},{"key":"488_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"488_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00488-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00488-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00488-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T05:33:49Z","timestamp":1681968829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00488-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00488-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}